Reported Reactions

Adverse event reports that FDA received

  • Search
  • Watch list

Renal disorder adverse event reports that record this term

Kind of term
MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on . The data have the reports that FDA received through .

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on .

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 46,004 adverse event reports that record the MedDRA preferred term Renal disorder. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 2,272 reports in the 12 months to June 2026 and 2,475 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 323 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 2,272 (0.2%) record this term. Reports for patients aged 18 to 44 were 6.1% of the reports that record this term and 12.3% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 43 drug pages with 250 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Drugs that the reports with the term Renal disorder name as a suspect product, in order of name
DrugClassReports with this term
AleveNonsteroidal anti-inflammatory drug262
AmbrisentanEndothelin receptor antagonist251
ApixabanFactor Xa inhibitor525
AranespErythropoiesis-stimulating agent422
CelebrexNonsteroidal anti-inflammatory drug383
CosentyxInterleukin-17A antagonist257
CrestorHMG-CoA reductase inhibitor307
EliquisFactor Xa inhibitor596
EnbrelTumor necrosis factor blocker835
EntrestoAngiotensin 2 receptor blocker1,022
ExjadeIron chelator323
ForteoParathyroid hormone analog276
HumalogInsulin analog437
Humira1,460
IbranceKinase inhibitor278
ImbruvicaKinase inhibitor296
JakafiJanus kinase inhibitor254
LantusInsulin analog276
Lantus SolostarInsulin analog251
LipitorHMG-CoA reductase inhibitor282
Lyrica350
MetforminBiguanide343
MethotrexateFolate analog metabolic inhibitor603
Metoprololbeta-Adrenergic blocker251
NexiumProton pump inhibitor679
Nexium 24HRProton pump inhibitor260
OmeprazoleProton pump inhibitor465
OpsumitEndothelin receptor antagonist278
PantoprazoleProton pump inhibitor288
Pantoprazole sodiumProton pump inhibitor270
PomalystThalidomide analog485
PrednisoneCorticosteroid557
PrevacidProton pump inhibitor495
Prevacid 24 HRProton pump inhibitor272
PrilosecProton pump inhibitor398
RemicadeTumor necrosis factor blocker294
RevlimidThalidomide analog2,030
RituximabCD20-directed cytolytic antibody356
SpironolactoneAldosterone antagonist287
TacrolimusCalcineurin inhibitor immunosuppressant356
TruvadaHuman immunodeficiency virus nucleoside analog reverse transcriptase inhibitor296
Vioxx922
XeljanzJanus kinase inhibitor530

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 57 pharmacologic classes with 250 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Pharmacologic classes of the drugs that the reports with the term Renal disorder name, in order of name
ClassReports with this term
Aldosterone antagonist307
Alkylating drug284
Aminoketone381
Angiotensin 2 receptor blocker1,861
Angiotensin converting enzyme inhibitor346
Anti-epileptic agent281
Antimetabolite immunosuppressant429
Atypical antipsychotic866
Benzodiazepine440
beta-Adrenergic blocker497
beta2-Adrenergic agonist456
Biguanide598
Bisphosphonate323
Calcineurin inhibitor immunosuppressant1,051
CD20-directed cytolytic antibody632
Complement inhibitor253
Corticosteroid1,912
Endothelin receptor antagonist935
Erythropoiesis-stimulating agent502
Factor Xa inhibitor1,261
Folate analog metabolic inhibitor882
GLP-1 receptor agonist835
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor324
Herpes simplex virus nucleoside analog DNA polymerase inhibitor334
HMG-CoA reductase inhibitor902
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor479
Insulin331
Insulin analog1,592
Integrin receptor antagonist282
Interferon beta358
Interleukin-17A antagonist307
Interleukin-4 receptor alpha antagonist271
Interleukin-6 receptor antagonist271
Iron chelator374
Janus kinase inhibitor1,019
Kinase inhibitor2,819
Leukotriene receptor antagonist259
Loop diuretic315
Nonsteroidal anti-inflammatory drug1,581
Nucleoside metabolic inhibitor355
Opioid agonist1,523
Osmotic laxative501
Parathyroid hormone analog299
Platinum-based drug286
Poly(ADP-Ribose) polymerase inhibitor333
Programmed death Receptor-1 blocking antibody710
Prostacycline vasodilator453
Proteasome inhibitor295
Proton pump inhibitor4,183
Provitamin D2 compound330
RANK ligand inhibitor285
Selective T cell costimulation modulator297
Serotonin reuptake inhibitor315
Sodium-Glucose cotransporter 2 inhibitor636
Thalidomide analog2,731
Tumor necrosis factor blocker1,764
Vascular endothelial growth factor inhibitor320

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Renal disorder, by month, five years to June 2026
025050020222023202420252026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Renal disorder
AgeReportsShareShare as a bar
Under 21070.2%
2 to 112150.5%
12 to 172420.5%
18 to 442,8136.1%
45 to 649,00319.6%
65 to 746,81014.8%
75 and over6,00013%
Age not given20,81445.2%
Sex of the patient in the reports that record Renal disorder
SexReportsShareShare as a bar
Female22,89549.8%
Male18,65040.5%
Unknown or not given4,4599.7%

Age and sex are as the report gives them. 65.3% of these reports give the United States as the country.

Terms near this one

Official pages

The site checked these addresses on . The links open in a new tab.

Cite this page

Embed this card on your site

Copy this code into your page. The card shows the figures above with their source. A line under the card links to this page.

How embedding works. It is free. Keep the link in the card and the link line under it.

Reported Reactions. Renal disorder: adverse event reports that record this term. https://reportedreactions.com/reaction/renal-disorder/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of . Reports received through .

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Renal disorder mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.

Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on .